Skip to main content

Table 1 Immunization history and baseline characteristics of rhesus macaques prior to tenofovir treatment

From: Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques

    SIVmac239Δnef proviral load   Lymphocyte counts (cells/mm3)d SIVmac239Δnef plasma viral loade
Macaque SIV infectiona Protection against SIVmac251 challengeb DNA copies/106 genomic equivalentsc Tenofovir CD4+ T cells CD8+ T cells (RNA copies/ml plasma
P512 - ND ND + 1039 705 < 50
P679 - ND ND + 793 609 < 50
P804 - ND ND + 989 847 < 50
P806 - ND ND + 512 371 < 50
1494 SIVmac239Δnef + 29 ± 23 - 558 ± 21 520 ± 75 1.5 × 103
1512 SIVmac239Δnef + 14 ± 9 - 868 ± 207 864 ± 269 5.5 × 102
1488 SIVmac239Δnef + 66 ± 41 + 725 ± 82 753 ± 208 < 50
1498 SIVmac239Δnef + 12 ± 10 + 669 ± 61 1471 ± 343 3.5 × 103
1514 SIVmac239Δnef + 291 ± 123 + 703 ± 180 963 ± 342 < 50
  1. a Macaques were infected with SIVmac239Δnef approximately 3 years prior to initiation of this study [16]
  2. b Challenge with SIVmac251 was carried out from 10 and 25 weeks after immunization with SIVmac239Δnef [16]
  3. c Mean ± standard deviation of 5–7 time points within 2.5 years before administration of tenofovir
  4. d Mean ± standard deviation of days -14, -6 and 0 before administration of tenofovir
  5. e Day 0 before administration of tenofovir